Page 6 – Channelchek

Bristol Myers Squibb Expands Cell Therapy Reach with $1.5 Billion Acquisition of Orbital Therapeutics

Posted on October 10, 2025October 10, 2025 by cpatches

Deal strengthens BMS’s leadership in cell therapy and adds next-generation RNA platform for in vivo CAR-T development

Bristol Myers Squibb (NYSE: BMY) announced it will acquire Orbital Therapeutics, a privately held biotechnology company pioneering RNA medicines designed to reprogram the immune system in vivo. The $1.5 billion all-cash deal expands BMS’s industry-leading cell therapy portfolio with Orbital’s proprietary RNA technology and its lead preclinical candidate, OTX-201, a next-generation CAR T-cell therapy for autoimmune diseases.

Orbital’s OTX-201 uses circular RNA encoding a CD19-targeted CAR, delivered via lipid nanoparticles (LNPs), to trigger in vivo expression of CAR T-cells — effectively transforming the patient’s own body into a CAR T-cell manufacturing system. This approach could significantly reduce treatment burden and broaden accessibility compared to traditional ex vivo CAR T-cell therapies.

The transaction, subject to customary closing conditions and regulatory review under the Hart-Scott-Rodino Act, marks Bristol Myers Squibb’s first major acquisition of 2025. The company has been seeking to diversify beyond mature blockbusters such as Eliquis and Revlimid, reinforcing investor confidence in its long-term growth trajectory through next-generation therapies.

“This agreement with Bristol Myers Squibb, a recognized leader in global medicine, marks a transformational moment for Orbital and the advancement of RNA medicine,” said Ron Philip, Chief Executive Officer of Orbital Therapeutics. “The promising early data from our lead program underscore the potential of our integrated RNA technologies to deliver simpler, safer, and more accessible treatments.”

“With the acquisition of Orbital Therapeutics and its next-generation RNA platform, we have an incredible opportunity to make CAR T-cell therapy more efficient and accessible to more patients,” added Lynelle B. Hoch, President of BMS’s Cell Therapy Organization.

Orbital’s RNA platform integrates circular and linear RNA engineering, advanced LNP delivery, and AI-driven design to enable programmable RNA therapies that can be tailored to a wide range of diseases. Beyond its autoimmune focus, the technology could have broad applications across oncology and other immune-mediated disorders.

This move positions BMS alongside other major pharmaceutical companies racing to develop in vivo cell therapies. AbbVie acquired Capstan Therapeutics in a $2.1 billion deal in June, Gilead’s Kite Pharma purchased Interius BioTherapeutics for $350 million in August, and AstraZeneca made a $1 billion buyout of EsoBiotec earlier this year.

BMS has been steadily building its cell therapy capabilities since its 2019 acquisition of Celgene, which brought in CAR T programs from bluebird bio and Juno Therapeutics. Earlier this year, it also acquired 2seventy bio for $286 million, consolidating full ownership of Abecma, a CAR T therapy for multiple myeloma.

Founded in 2022 and backed by Arch Venture Partners and other investors, Orbital Therapeutics raised $270 million in 2023 to advance its RNA platform under the leadership of former Spark Therapeutics CEO Ron Philip. The company identified in vivo CAR T-cell therapies as its first clinical focus — a vision that now aligns with BMS’s strategy to drive innovation in autoimmune and cell-based therapies.

AZZ (AZZ) – A Multi-Year Growth Story

Posted on October 10, 2025October 10, 2025 by cpatches

Friday, October 10, 2025

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

FY 2026 second-quarter results. AZZ reported adjusted net income of $46.9 million, or $1.55 per share, compared to $41.3 million, or $1.37 per share, during the prior year period. We projected adjusted net income of $46.7 million, or $1.54 per share. Compared to the second quarter of FY 2025, total sales increased 2.0% to $417.3 million. We had projected sales of $428.3 million. Gross margin of $101.3 million was modestly below our estimate of $104.7 million. Adjusted EBITDA declined modestly to $88.7 million compared to $91.9 million during the prior year period and our estimate of $93.4 million. Adjusted EBITDA margin as a percentage of sales declined to 21.3% compared to 22.5% during the prior year quarter.

Updating estimates. We have lowered our FY 2026 revenue, adjusted EBITDA, and adjusted EPS estimates to $1.642 billion, $369.2 million, and $5.98 per share, respectively, from $1.660 billion, $374.9 million, and $6.00 per share. Our revised forecasts reflect second-quarter results and more moderate sales growth in the second half of the year. Our longer-term estimates through FY 2031 reflect multi-year growth and are summarized at the end of this report. Our estimates could prove conservative if AZZ is successful in consummating acquisitions, which we do not reflect in our estimates until announced.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

Runway Growth Finance to Acquire SWK Holdings in $220 Million NAV-for-NAV Merger

Posted on October 10, 2025October 10, 2025 by cpatches

Transaction expands Runway’s healthcare and life sciences footprint and strengthens its specialty finance platform

Runway Growth Finance Corp. (Nasdaq: RWAY) announced it has entered into a definitive merger agreement to acquire SWK Holdings Corporation (Nasdaq: SWKH) in a net asset value (“NAV”)-for-NAV transaction valued at approximately $220 million, based on SWK’s June 30, 2025 financials and estimated transaction expenses. The deal combines two specialty finance firms with complementary portfolios and shared focus on non-dilutive, growth-oriented capital solutions.

Under the terms of the agreement, consideration to SWK stockholders will include $75.5 million in Runway Growth shares valued at closing NAV per share and approximately $145 million in cash, subject to final NAV adjustments prior to closing. In addition, Runway Growth Capital LLC, Runway’s external investment adviser and an affiliate of BC Partners Advisors L.P., will contribute $9 million in cash to SWK stockholders, separate from the primary merger consideration.

Strategic Expansion in Healthcare and Life Sciences

The merger significantly enhances Runway’s exposure to the healthcare and life sciences sectors. Upon completion, healthcare investments will comprise approximately 31% of Runway’s portfolio, up from 14% as of June 30, 2025. The combined company will have an estimated $1.3 billion in total assets, providing greater scale, diversification, and a broader investment platform for future growth.

SWK Holdings specializes in providing minimally dilutive financing to small- and mid-sized, commercial-stage healthcare companies through structured debt, royalty monetization, and asset-based transactions. Integrating SWK’s portfolio and experienced life sciences team will expand Runway’s deal sourcing and underwriting capabilities in one of the fastest-growing areas of specialty finance.

Enhanced Financial Profile and Growth Opportunities

Runway expects the transaction to be accretive to net investment income (NII) by the first full quarter post-closing, generating mid-single-digit run-rate NII accretion, while improving dividend coverage and return on equity (ROE). The company also anticipates a pro forma leverage ratio increase, expanding its nominal borrowing capacity and supporting continued risk-adjusted returns.

“This transaction meaningfully advances our strategy to diversify and optimize our portfolio by adding SWK’s high-quality investments in healthcare and life sciences,” said David Spreng, Founder and CEO of Runway Growth Finance. “We’re enhancing our earnings power while reinforcing portfolio strength and positioning for long-term value creation. With the support of BC Partners, we continue to pursue both organic and inorganic growth opportunities as a permanent capital vehicle backed by the $10 billion BC Partners Credit platform.”

A Repeatable Blueprint for Growth

Runway described the merger as a non-dilutive, repeatable model for future transactions within the venture and growth lending ecosystem. The company expects to benefit from both expanded scale and greater market visibility through the issuance of Runway Growth shares to SWK stockholders, broadening its shareholder base and trading liquidity.

Company Overviews

Runway Growth Finance Corp. is a specialty finance company providing flexible debt and structured financing to late- and growth-stage companies seeking an alternative to equity dilution. The company operates as a closed-end investment fund regulated as a business development company (BDC) under the Investment Company Act of 1940 and is externally managed by Runway Growth Capital LLC.

SWK Holdings Corporation is a life sciences-focused specialty finance company that partners with small- and mid-sized healthcare firms to fund the development and commercialization of medical technologies. Its customized financing solutions typically range from $5 million to $25 million and are designed to support long-term value creation while minimizing equity dilution.

Release – SKYX Provides Corporate Update Including an Additional $3.25 Million Investment from Leading Investor and Continued Expansion in Builder Segments

Posted on October 9, 2025October 9, 2025 by aweinsoff@channelchek.com

Research News and Market Data on SKYX

October 09, 2025 11:00 ET | Source: SKYX Platforms Corp.

MIAMI, Oct. 09, 2025 (GLOBE NEWSWIRE) — SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the “Company” or “SKYX”), a highly disruptive platform technology company with over 100 pending and issued patents globally and over 60 lighting and home décor websites, with a mission to make homes and buildings become safe and smart as the new standard, today provided the following corporate updated on its progress.

Market Acceptance, Progress and Recent Events:

After reporting 15.7 million in cash and cash equivalents as of June 30, 2025, SKYX has raised an additional $3.25 million in September from an existing lead investor.
SKYX has successfully demonstrated its technology during a Marriott Hotel renovation, incorporating its advanced and smart plug & play technologies, including ceiling lighting, recessed lights, downlights, wall lights, EXIT, and EMERGENCY lights, plug-in LED backlight mirrors among others. For Marriott video demo CLICK HERE.
SKYX will supply more than 10,000 of its advanced smart plug-and-play technologies to a 278-apartment project in Austin, Texas, being developed by Landmark Companies — a prominent developer with 27 years of experience and a track record of building tens of thousands of modern homes and buildings across Texas, Florida, Colorado, and other locations. For information about Landmark Companies projects Click Here.
SKYX is expected to deploy over 500,000 units of its advanced Plug & Play smart home technologies to Miami’s $3 billion mixed-use Urban Smart Home City project, located in the heart of the city. The Plug & Play smart home technologies will include SKYX’s AI-powered ecosystem, its all-in-one smart home platform technology, as well as ceiling lighting, recessed lights, downlights, wall lights, EXIT, and EMERGENCY lights, plug-in LED backlight mirrors among others. SKYX’s full suite of smart platform products will be utilized throughout the entire project.
The groundbreaking Smart Home Mixed-Use Major Urban Development Will Redefine Miami’s Urban Landscape
The architecture and design of the Miami Smart Home City is led by world-renowned architectural firm Arquitectonica. The $3 billion development is led by SG Holdings, a distinguished joint venture comprised of Swerdlow Group, SJM Partners, and Alben Duffie—each renowned for transformative urban projects.
SKYX has financial backing from U.S. and global manufacturers to support its massive product deployment.
SKYX’s Safety Code Standardization Team has gained the support of a prominent new leader who is actively engaging with key government safety organizations — marking a significant step forward in the Company’s efforts to establish mandatory safety standardization for its advanced safe ceiling technologies.
SKYX is progressing toward a winter launch of its turbo heater & ceiling fan to support its path to cash-flow positivity in 2025. The ceiling fan and space heater category represents a multi-billion-dollar market with tens of millions of units sold annually in the U.S.
Management is expecting to secure additional significant business opportunities.
Company expects its products to be in 50,000 U.S. and Canadian units-home Management expects to achieve its goal of being cash flow positive by the end of 2025.
SKYX revenues increased for 6 comparable quarters from Q1 2024 through Q2 2025 with $19M in Q1/24, 21.4M in Q2/24, $22.2M in Q3/24, $23.7M in Q4/24, $20.1M in Q1/25, and $23.1M in Q2/25
Net cash used in operating activities for the Second quarter ending June 30, 2025, decreased sequentially by 54% to $2.0 million compared to $4.3 million in the First quarter of 2025.
The gross profit for the Second quarter ending June 30, 2025, increased sequentially by 23% to $7.0 million, compared to the First quarter ending March 31, 2025.
The gross margin for the Second quarter ending June 30, 2025, increased sequentially by 7% to 30.3%, compared to the First quarter ending March 31, 2025.
Management expects to achieve its goal of being cash flow positive by the end of 2025.
SKYX revenues increased for 6 comparable quarters from Q1 2024 through Q2 2025 with $19M in Q1/24, $21.4M in Q2/24, $22.2M in Q3/24, $23.7M in Q4/24, $20.1M in Q1/25, and $23.1M in Q2/25
Net cash used in operating activities for the Second quarter ending June 30, 2025, decreased sequentially by 54% to $2.0 million compared to $4.3 million in the First quarter of 2025.
The gross profit for the Second quarter ending June 30, 2025, increased sequentially by 23% to $7.0 million, compared to the First quarter ending March 31, 2025.
The gross margin for the Second quarter ending June 30, 2025, increased sequentially by 7% to 30.3%, compared to the First quarter ending March 31, 2025.
Over the past year, SKYX has secured a total of $15 million in investments from strategic investors, led by global Marriott Hotel chain owner. The round also included significant participation from company insiders — including SKYX President Steve Schmidt, CEO Lenny Sokolow and former CEO John Campi — underscoring their continued confidence in SKYX’s strategic vision and growth trajectory.
As common with companies such as ours when sales are converted into cash rapidly, often referred to as the “Dell Working Capital Model”, the Company leverages its trades payable to finance its operations, to enhance its cash position and to lower its cost of capital.
The Company announced a U.S. strategic manufacturing partnership with Profab Electronics, a premier electronics contract manufacturer based in Pompano Beach, Florida. This collaboration marks a significant step forward in SKYX’s commitment to building a resilient, efficient, and localized supply chain for its innovative product lines. This is in addition to manufacturing collaborations in Vietnam, Taiwan, China and Cambodia.
The Company strongly believes its products have the potential to save insurance companies billions of dollars annually by reducing the risks of fires, ladder falls, electrocutions, and other related incidents. Management expects that once the full range and variations of its safe plug-and-play products are completed, they will begin to be recommended by insurance companies.
SKYX’s technologies provide opportunities for recurring revenues through interchangeability, upgrades, monitoring, and subscriptions. Company is focused on the “Razor & Blades” model and its product range includes its advanced ceiling electrical outlet (Razor) and its advance and smart home plug & play products (Blades) including its advance and smart home plug & play platform products, lighting, recessed lights, down lights, EXIT signs, emergency lights, ceiling fans, chandeliers/pendants, holiday/kids/themes lights, indoor/outdoor wall lights among other. Company’s plug & play technology enables an installation of lighting, fans, and smart home products in high-rise buildings and hotels within days rather than months.
Company’s total addressable market (TAM) in the U.S. is roughly $500 billion with over 4.2 billion ceiling applications in the U.S. alone. Expected revenue streams from retail and professional segments include product sales, royalties, licensing, subscription, monitoring, and sale of global country rights.
Company continues to utilize its e-commerce platform of over 60 websites for lighting and home décor to educate and enhance its market penetration to both retail and professional segments.
Company is collaborating with Home Depot and Wayfair for Its Advanced and Smart Plug & Play products for both retail and professional segments. SKYX’s product offering will include a variety of its advanced and Smart Plug & Play products including Retrofit Kits, Smart Light Fixtures, Smart Ceiling Fans, Ceiling Outlet Receptacles, Recessed Lights and more.
SKYX collaborates with U.S. and world leading lighting companies including Kichler Quoizel, European leading company, EGLO, and worlding lighting manufacturer Ruee.
Collaborated with Cavco Homes, a leading U.S. prefabricated home manufacturer, for integrating our advanced and smart plug & play technologies into Cavco’s high-end premium homes shown at the builder show. Cavco is a public company that has sold nearly one million homes and continues to deliver close to 20,000 annually.
Three luxury developments by Forte Developments, including an 80-story high-rise in Miami’s Brickell District and projects in Clearwater Beach and Jupiter, Florida, will feature SKYX’s technology. More than 12,000 smart plug & play products, including ceiling outlets, lighting, fans, and emergency fixtures, will be supplied across 400+ units. A 1,000-unit mixed-use development by Jeremiah Baron Companies will incorporate smart plug & play technologies, with 140 units receiving initial product supply. This product rollout will include ceiling outlets, lighting, fans, and emergency fixtures, with deliveries continuing throughout construction.
A strategic partnership with JIT Electrical Supply, a leading builder supplier, will expand SKYX’s footprint in electrical, lighting, and ceiling fan markets. JIT, which has supplied over 100,000 U.S. homes, will distribute SKYX’s lighting solutions, ceiling fans, recessed lights, emergency lights, exit signs, and indoor/outdoor wall lights beginning early 2025.
Huey Long, former Amazon E-Commerce Director and executive at Walmart and Ashley Furniture, has joined as head of SKYX’s e-commerce platform. He will collaborate with the existing team to expand market penetration across 60 lighting and home décor websites and other key e-commerce channels in the U.S. and Canada.

Safety Standardization Mandatory Code / Insurance Specification and Recommendation

SKYX’s Safety Code Standardization Team is receiving support from a new significant prominent leader with its government safety agency’s process for a safety mandatory standardization of its electrical ceiling outlet/receptacle technology.
SKYX’s code team, led by industry veterans Mark Earley, former head of the National Electrical Code (NEC), and Eric Jacobson, former President and CEO of the American Lighting Association (ALA). Company’s safety Code Standardization team believes it will achieve assistance from additional safety organizations with its code mandatory safety standardization efforts based on the product’s significant safety aspects. Mr. Earley and Mr. Jacobson were instrumental in numerous code and safety changes in both the electrical and lighting industries. Both strongly believe that, considering the Company’s standardization progress including its product specification approval voting for by ANSI / NEMA (American National Standardization Institute / National Electrical Manufacturers Association) and being voted into 10 segments in the NEC Code Book, it has met the necessary safety conditions for becoming a ceiling safety standardization requirement for homes and buildings.
With respect to insurance companies, the Company strongly believes its products can save insurance companies many billions of dollars annually by reducing fires, ladder falls, and electrocutions among other things. Management expects that once it completes an entire range and variations of its safe advanced plug & play products it will start being recommended by insurance companies.

To view SKYX’s Technologies demo video Click Here

About SKYX Platforms Corp.

As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced-safe-smart platform technologies, with over 100 U.S. and global patents and patent pending applications. Additionally, the Company owns over 60 lighting and home decor websites for both retail and commercial segments. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at https://skyplug.com/ or follow us on LinkedIn.

Forward-Looking Statements

Certain statements made in this press release are not based on historical facts but are forward-looking statements. These statements can be identified by the use of forward-looking terminology such as “aim,” “anticipate,” “believe,” “can,” “could,” “continue,” “estimate,” “expect,” “evaluate,” “forecast,” “guidance,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “outlook,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “target” “view,” “will,” or “would,” or the negative thereof or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements reflect the Company’s reasonable judgment with respect to future events and are subject to risks, uncertainties and other factors, many of which have outcomes difficult to predict and may be outside our control, that could cause actual results or outcomes to differ materially from those in the forward-looking statements. Such risks and uncertainties include statements relating to the Company’s ability to successfully launch, commercialize, develop additional features and achieve market acceptance of its products and technologies and integrate its products and technologies with third-party platforms or technologies; the Company’s efforts and ability to drive the adoption of its products and technologies as a standard feature, including their use in homes, hotels, offices and cruise ships; the Company’s ability to capture market share; the Company’s estimates of its potential addressable market and demand for its products and technologies; the Company’s ability to raise additional capital to support its operations as needed, which may not be available on acceptable terms or at all; the Company’s ability to continue as a going concern; the Company’s ability to execute on any sales and licensing or other strategic opportunities; the possibility that any of the Company’s products will become National Electrical Code (NEC)-code or otherwise code mandatory in any jurisdiction, or that any of the Company’s current or future products or technologies will be adopted by any state, country, or municipality, within any specific timeframe or at all; risks arising from mergers, acquisitions, joint ventures and other collaborations; the Company’s ability to attract and retain key executives and qualified personnel; guidance provided by management, which may differ from the Company’s actual operating results; the potential impact of unstable market and economic conditions on the Company’s business, financial condition, and stock price; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including its periodic reports on Form 10-K and Form 10-Q. There can be no assurance as to any of the foregoing matters. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by U.S. federal securities laws.

Investor Relations Contact:
Jeff Ramson
PCG Advisory
jramson@pcgadvisory.com

Release – Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

Posted on October 9, 2025October 9, 2025 by aweinsoff@channelchek.com

Research News and Market Data on GLSI

Download as PDF October 09, 2025 6:00am EDT

STAFFORD, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Austria.

The Company’s application to European regulators has been formally approved, adding Austria as an approved country in FLAMINGO-01 in addition to Spain, France, Germany, Italy, Poland, Romania, Ireland, Portugal, Belgium, and the US.

According to the latest data collected by the European Cancer Information System (click here), a total of 6,070 new cases of breast cancer were diagnosed in Austria in 2022, which is the most common cancer diagnosed in women, representing approximately 28% of all cancers in women. Breast cancer is the leading cause of death from cancer in women in Austria with 1,789 deaths in 2022.

CEO Snehal Patel commented, “We are collaborating with principal investigators at the Ordensklinikum Linz in Upper Austria. The site approached the Company after patients asked about participating in FLAMINGO-01. We recently visited the site in Linz, where we started training activities. We hope to activate the site this year and plan to further develop the geographic strategy for Austria, where we are considering additional sites in Vienna and Salzburg.”

About FLAMINGO-01 and GLSI-100

FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types will be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater.

For more information on FLAMINGO-01, please visit the Company’s website here and clinicaltrials.gov here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the “Contacts and Locations” section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: flamingo-01@greenwichlifesciences.com

About Breast Cancer and HER2/neu Positivity

One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company’s website at www.greenwichlifesciences.com and follow the Company’s Twitter at https://twitter.com/GreenwichLS.

Forward-Looking Statement Disclaimer

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled “Risk Factors” in Greenwich LifeSciences’ Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.

Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: info@greenwichlifesciences.com

Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: dave@redchip.com

Source: Greenwich LifeSciences, Inc.

Released October 9, 2025

Novo Nordisk Acquires Akero Therapeutics in $5.2 Billion Deal to Bolster MASH Treatment Pipeline

Posted on October 9, 2025October 9, 2025 by slightbourne@noblecapitalmarkets.com

Novo Nordisk is making another bold move in the metabolic disease space with its latest agreement to acquire Akero Therapeutics for up to $5.2 billion, marking one of the year’s largest biotech takeovers. The deal strengthens Novo Nordisk’s expanding presence in liver and metabolic disorders, while delivering significant value to Akero’s shareholders.

Under the terms of the agreement announced Thursday, Akero investors will receive $54 per share in cash at closing, plus a contingent value right (CVR) worth up to an additional $6 per share. The CVR payment would be triggered upon full U.S. regulatory approval of Akero’s lead drug candidate, efruxifermin (EFX), for treating compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) by June 2031.

The acquisition values Akero at roughly $4.7 billion upfront, representing a 42% premium to its pre-rumor share price earlier this year. If all conditions are met, the total value could reach $5.2 billion — a 57% premium compared to Akero’s May 2025 valuation.

For Novo Nordisk, the deal builds on its leadership in GLP-1–based therapies and signals a deepening commitment to addressing complex metabolic diseases. Akero’s EFX program, designed to treat MASH, a condition historically known as NASH (nonalcoholic steatohepatitis), complements Novo Nordisk’s existing pipeline of cardiometabolic treatments. EFX’s potential to reverse fibrosis and improve liver function positions it as a promising therapy for millions of patients with few available options.

MASH has become a growing global health concern, closely linked to obesity and type 2 diabetes—areas where Novo Nordisk already dominates through blockbuster drugs like Ozempic and Wegovy. Integrating Akero’s research could help the Danish pharmaceutical giant extend its reach beyond diabetes and into liver health, strengthening its competitive advantage as demand for metabolic therapies surges worldwide.

Industry analysts see the deal as part of a broader wave of consolidation among biotechs developing metabolic and inflammatory treatments. Major pharmaceutical companies are increasingly acquiring smaller firms with advanced-stage assets to accelerate innovation and diversify revenue streams.

Akero’s ongoing Phase 3 SYNCHRONY trials have shown encouraging signs that EFX can reduce fibrosis and resolve MASH, potentially transforming the standard of care. The company’s holistic approach — improving both liver health and cardiovascular risk factors — aligns well with Novo Nordisk’s long-term goal of offering comprehensive solutions for metabolic dysfunction.

Following the acquisition, Akero’s operations will be integrated into Novo Nordisk’s global research network, with plans to advance EFX through late-stage trials and prepare for commercial launch. The transaction, unanimously approved by Akero’s board, is expected to close by year-end pending shareholder and regulatory approvals.

Financial advisors for the deal include Morgan Stanley and J.P. Morgan Securities, with Kirkland & Ellis LLP serving as legal counsel to Akero.

The acquisition underscores Novo Nordisk’s strategy to expand beyond diabetes and obesity treatments into adjacent metabolic diseases with large unmet medical needs. If EFX achieves approval and commercial success, the deal could mark a defining moment in the evolution of liver disease therapeutics—and another milestone in Novo Nordisk’s transformation into a powerhouse across metabolic health.

Resources Connection (RGP) – First Look at 1Q26

Posted on October 9, 2025October 9, 2025 by slightbourne@noblecapitalmarkets.com

Thursday, October 09, 2025

Resources Connection, Inc. provides agile consulting services in North America, Europe, and the Asia Pacific. The company offers finance and accounting services, including process transformation and optimization, financial reporting and analysis, technical and operational accounting, merger and acquisition due diligence and integration, audit readiness, preparation and response, implementation of new accounting standards, and remediation support. It also provides information management services, such as program and project management, business and technology integration, data strategy, and business performance management. In addition, the company offers corporate advisory, strategic communications, and restructuring services; and corporate governance, risk, and compliance management services, such as contract and regulatory compliance, enterprise risk management, internal controls management, and operation and information technology (IT) audits. Further, it provides supply chain management services comprising strategy development, procurement and supplier management, logistics and materials management, supply chain planning and forecasting, and unique device identification compliance; and human capital services, including change management, organization development and effectiveness, compensation and incentive plan strategies, and optimization of human resources technology and operations. Additionally, the company offers legal and regulatory supporting services for commercial transactions, global compliance initiatives, law department operations, and law department business strategies and analytics. It also provides policyIQ, a proprietary cloud-based governance, risk, and compliance software application. The company was formerly known as RC Transaction Corp. and changed its name to Resources Connection, Inc. in August 2000. Resources Connection, Inc. was founded in 1996 and is headquartered in Irvine, California.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

A Beat. Resources Connection reported first quarter revenue, gross margin, and SG&A expenses better than expected, although the top line continued to decline y-o-y, as expected. RGP is engaging with clients on more consulting opportunities, which have higher bill rates, larger deal size, and often create more extension and cross selling. However, the macro environment remains unpredictable, which makes clients hesitant to begin new projects.

Details. 1Q26 revenue came in at $120.2 million, down from $136.9 million in 1Q25, but above the $120 million high-end of management’s guidance. Gross margin came in at 39.5%, a significant y-o-y improvement from 36.5% in 1Q25 and above the 36-37% guidance range. SG&A expense of $47.9 million improved from $48.9 million in 1Q25. RGP recorded a GAAP net loss of $2.4 million, or $0.07/sh, compared to a $5.7 million, or $0.17/sh, net loss, in 1Q25. Adjusted EPS was $0.03/sh versus breakeven last year.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Bit Digital (BTBT) – Monthly Ethereum Metrics

Posted on October 9, 2025October 9, 2025 by slightbourne@noblecapitalmarkets.com

Thursday, October 09, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Data. Bit Digital reported its monthly Ethereum (“ETH”) treasury and staking metrics for the month of September 2025. As of September 30, 2025, the Company held approximately 121,187 ETH, versus 121,252 ETH at the end of August. Included in the ETH holdings were approximately 15,075 ETH and ETH-equivalents held in an externally managed fund, and approximately 5,142 ETH presented on an as-converted basis from LsETH using the Coinbase conversion rate as of 9/30/25. The Company’s total staked ETH was approximately 99,936 as of September 30th.

Yield and Value. Staking operations generated approximately 291 ETH in rewards during September, representing an annualized yield of approximately 3.37%. Based on a closing ETH price of $4,145.99, as of September 30, 2025, the market value of the Company’s ETH holdings was approximately $506.6 million.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

AZZ (AZZ) – Staying Focused on the Big Picture

Posted on October 9, 2025October 9, 2025 by slightbourne@noblecapitalmarkets.com

Thursday, October 09, 2025

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

FY 2026 second-quarter financial results. AZZ reported adjusted net income of $46.9 million, or $1.55 per share, compared to $41.3 million, or $1.37 per share, during the prior year period. We had forecast adjusted net income of $46.7 million, or $1.54 per share. Compared to the second quarter of FY 2025, total sales increased 2.0% to $417.3 million. We had projected sales of $428.3 million. Gross margin of $101.3 million was modestly below our estimate of $104.7 million. Sales and gross margins trailed our expectations for both segments. However, operating income of $68.5 million exceeded our estimate of $66.1 million due to lower selling, general, and administrative expenses. Adjusted EBITDA declined modestly to $88.7 million compared to $91.9 million during the prior year period and our estimate of $93.4 million. Adjusted EBITDA margin as a percentage of sales declined to 21.3% compared to 22.5% during the second quarter of FY 2025.

Results were mixed. While Metal Coatings sales were up 10.8% compared to the prior year quarter, Precoat Metals sales were down 4.3%. Metal Coatings delivered higher sales due to increased volume driven by infrastructure-related projects in several end markets. Precoat Metals experienced lower sales due to weaker end markets, including building construction, HVAC, and appliance.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Silver Breaks $50: Precious Metal Hits Four-Decade High as Investors Flock to Safe Havens

Posted on October 9, 2025October 9, 2025 by slightbourne@noblecapitalmarkets.com

Silver has shattered a historic milestone, climbing past $50 per ounce for the first time since 1980 — marking one of the most significant rallies in the metals market in over forty years. The surge, up roughly 75% year-to-date, underscores a powerful combination of investor demand, industrial consumption, and persistent supply shortages.

While gold has dominated headlines with its record-breaking ascent above $4,000 per ounce, silver’s breakout is capturing equal attention. Often referred to as “gold’s more affordable cousin,” silver is benefiting from the same wave of safe-haven buying driven by global economic uncertainty, political instability, and weakening confidence in traditional fiat currencies.

This rally isn’t just about market sentiment. Silver’s unique dual identity — as both an investment asset and a critical industrial material — has amplified its momentum. The metal is an essential component in solar panels, electric vehicles, data centers, and smartphone manufacturing, making it a cornerstone of the modern green and tech economies.

“Silver’s industrial demand is skyrocketing, particularly with the ongoing boom in renewable energy and semiconductor expansion,” noted market strategists. “This growing utility, combined with investors seeking protection against inflation and currency risk, is creating a perfect storm for price growth.”

According to analysts, 2025 marks the fifth consecutive year of a structural supply deficit in the silver market. Sluggish mining output and limited new production are struggling to keep pace with global demand, further tightening supply. Many traders believe this imbalance could sustain elevated prices well into 2026.

Silver’s rally closely mirrors gold’s performance, but it’s also outpacing it in percentage terms. While gold has climbed around 51% this year, silver’s 75% surge and platinum’s 80% gain highlight the broad strength of the precious metals sector. The upward trend is being fueled by concerns about inflation, tariffs, central bank policy independence, and rising national debt levels.

At the institutional level, hedge funds and asset managers are rotating capital into tangible assets like precious metals and Bitcoin as a hedge against a weakening U.S. dollar. Exchange-traded funds (ETFs) tied to silver — particularly the iShares Silver Trust (SLV) — have seen record inflows not witnessed since 2020.

With demand surging and inventories thinning, analysts suggest silver may be entering a sustained breakout phase rather than a short-term spike. For retail and small-cap investors alike, the current rally presents both opportunity and volatility — hallmarks of a market on the move.

Gold Keeps Breaking Records as Global Demand Surges

Posted on October 9, 2025October 9, 2025 by slightbourne@noblecapitalmarkets.com

Gold prices have shattered records yet again, surging past $4,000 per ounce for the first time in history as investors continue to flock to the safe-haven asset amid global uncertainty and expectations of deeper Federal Reserve rate cuts. The yellow metal’s meteoric rise marks one of the strongest rallies in decades, gaining more than 50% year-to-date — its best annual performance since 1979.

According to data from the World Gold Council, global gold-backed exchange-traded funds (ETFs) saw their largest quarterly inflows on record, with investors pouring in more than $26 billion during the third quarter of 2025. North American funds led the surge, followed by European and Asian markets, as geopolitical tensions, volatile currencies, and concerns over central bank policy fueled the rush into gold.

Analysts noted that a combination of economic uncertainty, political instability, and weakening confidence in traditional currencies has been fueling record levels of investment in gold. They suggested that even modest shifts of capital away from the bond market toward gold could be enough to push prices significantly higher.

Gold’s recent rally has been closely tied to growing speculation that the Federal Reserve will continue cutting interest rates to support the slowing economy. Lower rates reduce the opportunity cost of holding non-yielding assets like gold, making it more attractive to both institutional and retail investors.

Meanwhile, the US dollar has weakened, further boosting gold’s appeal. As the greenback loses strength, international buyers gain more purchasing power, often resulting in increased gold demand.

The gold market’s explosive momentum has also led to a surge in trading activity. Average daily trading volumes climbed 34% month over month, hitting all-time highs as prices broke new records 13 times in September alone.

Wall Street remains bullish. Goldman Sachs has reaffirmed gold as its “highest-conviction long recommendation,” forecasting that continued monetary easing and persistent global tensions could keep driving the metal upward.

Analysts predicts that gold could reach $4,500 by mid-2026, with a potential breakout toward $5,000 per ounce if capital continues to rotate out of government bonds and into precious metals.

As global markets navigate uncertainty — from geopolitical flashpoints to currency instability — gold’s appeal as a safe, tangible store of value remains as strong as ever. For now, the metal’s relentless climb shows no signs of slowing.

Release – Saga Communications, Inc. Announces Investor Conference Presentation

Posted on October 8, 2025October 8, 2025 by aweinsoff@channelchek.com

Research News and Market Data on SGA

Oct 7, 2025

PDF Version

GROSSE POINTE FARMS, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) — Saga Communications, Inc. (Nasdaq – SGA) (the “Company,” “Saga,” “we” or “our”) announced today that Christopher S. Forgy, President and Chief Executive Officer and Samuel D. Bush, Executive Vice President, Chief Financial Officer and Treasurer will be presenting at the Noble Capital Markets’ Emerging Growth Virtual Equity Conference on October 8, 2025 at 4:00p (EDT). The presentation will feature a fireside style Q&A session with Michael Kupinski, Director of Research and Senior Media & Entertainment Analyst at Noble Capital Markets

Attendees interested in viewing the live presentation can register and access this event at:
https://www.meetmax.com/sched/event_125441/investor_reg_new.html?attendee_role_id=NOBLE_INVESTOR

A video webcast of the presentation will be available following the event on the Company’s website www.sagacom.com as soon as it is available, and as part of a complete catalog of presentations available on Channelchek www.channelchek.com, the investor portal created by Noble.

Saga is a media company whose business is devoted to acquiring, developing, and operating broadcast properties with a focus on providing opportunities complimentary to our core radio business including digital, e-commerce, local on-line news services, and non-traditional revenue initiatives. Saga owns or operates broadcast properties in 28 markets, including 82 FM and 31 AM radio stations and 79 metro signals. For additional information, contact us at (313) 886-7070 or visit our website at www.sagacom.com.

Noble Capital Markets was established in 1984. Noble Capital Markets is an SEC / FINRA registered full-service investment bank and advisory firm with an award-winning research team and proprietary investor distribution platform. Noble delivers middle market expertise to entrepreneurs, corporations, financial sponsors, and investors. Over the past 40 years, Noble has raised billions of dollars for companies and published more than 45,000 equity research reports.

This press release and the Company’s anticipated presentation contain certain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that are based upon current expectations and involve certain risks and uncertainties. Words such as “will,” “may,” “believes,” “intends,” “expects,” “anticipates,” “guidance,” and similar expressions are intended to identify forward-looking statements. The material risks facing our business are described in the reports Saga periodically files with the U.S. Securities and Exchange Commission, including, in particular, Item 1A of our Annual Report on Form 10-K. Readers should note that forward-looking statements may be impacted by several factors, including global, national, and local economic changes and changes in the radio broadcast industry in general as well as Saga’s actual performance. Actual results may vary materially from those described herein and Saga undertakes no obligation to update any information contained herein that constitutes a forward-looking statement.

Contact:
Samuel D. Bush
313/886-7070

Release – Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology

Posted on October 8, 2025October 8, 2025 by aweinsoff@channelchek.com

Research News and Market Data on NTRB

October 08, 2025 08:30 ET | Source: Nutriband Inc.

Nutriband files provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for abuse.

Nutriband’s AVERSA™ abuse-deterrent technology consists of a proprietary aversive agent coating that employs taste aversion to deter oral abuse and reduce accidental exposure.

ORLANDO, Fla., Oct. 08, 2025 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) to further strengthen Nutriband’s intellectual property protection for its AVERSA™ abuse deterrent transdermal technology.

The provisional patent application covers improved aversive formulations and coating application methods to enhance the abuse deterrent properties of Nutriband’s AVERSA™ transdermal technology and make it even more difficult to defeat. If this provisional patent application is converted into a non-provisional patent application and a new patent is subsequently granted, it could significantly extend the patent protection for products that utilize Nutriband’s AVERSA™ abuse deterrent technology as the statutory patent term of a US patent is 20 years from the non-provisional filing date.

The AVERSA™ abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

Nutriband’s AVERSA™ abuse-deterrent technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as opioids, while making sure that these drugs remain accessible to those patients who really need them.

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband’s AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, including opioids and stimulant drugs, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company’s website is www.nutriband.com. Any material contained in or derived from the Company’s websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words ‘’believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contact Information:

Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com

SOURCE: Nutriband Inc.